CBO Report Details How New Bill Weakens Medicare Drug Price Negotiation
What happened
The Congressional Budget Office reported that the One Big Beautiful Bill provided an $8.8 billion handout to Big Pharma. The bill weakened Medicare's ability to negotiate the price of certain drugs that have an "orphan drug designation". Congressman Bryan Steil voted for the bill after receiving a $500 contribution from pharma lobbyist Dan Todd.
From milwaukeecourier.com
Why it matters
The legislation weakens Medicare's ability to control drug costs. This change protects drug pricing for major pharmaceutical companies. Democratic Health Committee members stated the bill would undermine efforts to lower prescription drug prices for years to come.
From milwaukeecourier.com
Who's involved
- Congressional Budget OfficeGovernment agency that provided the financial analysis of the bill
- HouseLegislative body where the bill was voted on
- MedicareFederal health insurance program whose negotiation power was reduced
- AstraZenecaPharmaceutical company mentioned as benefiting from the bill
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Johnson & JohnsonSpeculative
Johnson & Johnson might see increased revenue potential as Medicare's negotiation power is reduced.
- AstraZenecaSpeculative
AstraZeneca may benefit from increased pricing power due to the weakened Medicare negotiation ability.
- GSKSpeculative
GSK could see a structural advantage in drug pricing following the bill's passage.
Keep exploring
The entities involved
-
Congressional Budget Office
government agency
- House
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer